CN110042137B - 高密度灌注培养重组cho细胞生产人促卵泡激素的方法、培养基及其应用 - Google Patents
高密度灌注培养重组cho细胞生产人促卵泡激素的方法、培养基及其应用 Download PDFInfo
- Publication number
- CN110042137B CN110042137B CN201910398124.2A CN201910398124A CN110042137B CN 110042137 B CN110042137 B CN 110042137B CN 201910398124 A CN201910398124 A CN 201910398124A CN 110042137 B CN110042137 B CN 110042137B
- Authority
- CN
- China
- Prior art keywords
- culture
- culture medium
- cell
- density
- sodium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000010412 perfusion Effects 0.000 title claims abstract description 73
- 239000001963 growth medium Substances 0.000 title claims abstract description 60
- 210000004978 chinese hamster ovary cell Anatomy 0.000 title claims abstract description 35
- 102000003864 Human Follicle Stimulating Hormone Human genes 0.000 title claims abstract description 33
- 108010082302 Human Follicle Stimulating Hormone Proteins 0.000 title claims abstract description 33
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 16
- 210000004027 cell Anatomy 0.000 claims abstract description 115
- 238000011010 flushing procedure Methods 0.000 claims abstract description 14
- 239000012510 hollow fiber Substances 0.000 claims abstract description 14
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 14
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 13
- 230000000694 effects Effects 0.000 claims abstract description 8
- 238000003756 stirring Methods 0.000 claims abstract description 3
- 239000007788 liquid Substances 0.000 claims description 30
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 27
- 239000008103 glucose Substances 0.000 claims description 27
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 claims description 24
- 239000000126 substance Substances 0.000 claims description 19
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 18
- 239000006143 cell culture medium Substances 0.000 claims description 15
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 14
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 14
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 14
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 14
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 14
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 14
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 14
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 14
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 14
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 14
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 14
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 14
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 14
- 229960002413 ferric citrate Drugs 0.000 claims description 14
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 14
- NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical compound [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 claims description 14
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 claims description 14
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 claims description 14
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 claims description 14
- 210000002966 serum Anatomy 0.000 claims description 14
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 claims description 14
- 230000003833 cell viability Effects 0.000 claims description 13
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 claims description 12
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 12
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 12
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 claims description 12
- 239000012526 feed medium Substances 0.000 claims description 12
- 239000001301 oxygen Substances 0.000 claims description 12
- 229910052760 oxygen Inorganic materials 0.000 claims description 12
- 229940054269 sodium pyruvate Drugs 0.000 claims description 12
- FWPIDFUJEMBDLS-UHFFFAOYSA-L tin(II) chloride dihydrate Chemical compound O.O.Cl[Sn]Cl FWPIDFUJEMBDLS-UHFFFAOYSA-L 0.000 claims description 12
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 claims description 10
- 235000018102 proteins Nutrition 0.000 claims description 10
- 235000002639 sodium chloride Nutrition 0.000 claims description 10
- 238000011081 inoculation Methods 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 239000001103 potassium chloride Substances 0.000 claims description 9
- 235000011164 potassium chloride Nutrition 0.000 claims description 9
- 239000007640 basal medium Substances 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- 230000001502 supplementing effect Effects 0.000 claims description 8
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 claims description 7
- RBMGJIZCEWRQES-DKWTVANSSA-N (2s)-2,4-diamino-4-oxobutanoic acid;hydrate Chemical compound O.OC(=O)[C@@H](N)CC(N)=O RBMGJIZCEWRQES-DKWTVANSSA-N 0.000 claims description 7
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 claims description 7
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 claims description 7
- KWTQSFXGGICVPE-UHFFFAOYSA-N 2-amino-5-(diaminomethylideneamino)pentanoic acid;hydron;chloride Chemical compound Cl.OC(=O)C(N)CCCN=C(N)N KWTQSFXGGICVPE-UHFFFAOYSA-N 0.000 claims description 7
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 claims description 7
- QAWLKTDBUQOFEF-UHFFFAOYSA-N 3-(4-bromophenyl)propanenitrile Chemical compound BrC1=CC=C(CCC#N)C=C1 QAWLKTDBUQOFEF-UHFFFAOYSA-N 0.000 claims description 7
- QVJPPFAOCXDDPW-UHFFFAOYSA-N 5-[chloro(difluoro)methyl]-1,2-oxazole Chemical compound FC(F)(Cl)C1=CC=NO1 QVJPPFAOCXDDPW-UHFFFAOYSA-N 0.000 claims description 7
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 7
- 235000019743 Choline chloride Nutrition 0.000 claims description 7
- 229910021555 Chromium Chloride Inorganic materials 0.000 claims description 7
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 7
- 239000004471 Glycine Substances 0.000 claims description 7
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims description 7
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 claims description 7
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 7
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 7
- 229930064664 L-arginine Natural products 0.000 claims description 7
- 235000014852 L-arginine Nutrition 0.000 claims description 7
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 7
- 229930182816 L-glutamine Natural products 0.000 claims description 7
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 7
- 229930182844 L-isoleucine Natural products 0.000 claims description 7
- 239000004395 L-leucine Substances 0.000 claims description 7
- 235000019454 L-leucine Nutrition 0.000 claims description 7
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 claims description 7
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 7
- 229930195722 L-methionine Natural products 0.000 claims description 7
- 229930182821 L-proline Natural products 0.000 claims description 7
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 7
- 239000005700 Putrescine Substances 0.000 claims description 7
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 7
- 239000004473 Threonine Substances 0.000 claims description 7
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims description 7
- 239000012378 ammonium molybdate tetrahydrate Substances 0.000 claims description 7
- 229960001230 asparagine Drugs 0.000 claims description 7
- FIXLYHHVMHXSCP-UHFFFAOYSA-H azane;dihydroxy(dioxo)molybdenum;trioxomolybdenum;tetrahydrate Chemical compound N.N.N.N.N.N.O.O.O.O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O[Mo](O)(=O)=O.O[Mo](O)(=O)=O.O[Mo](O)(=O)=O FIXLYHHVMHXSCP-UHFFFAOYSA-H 0.000 claims description 7
- UNTBPXHCXVWYOI-UHFFFAOYSA-O azanium;oxido(dioxo)vanadium Chemical compound [NH4+].[O-][V](=O)=O UNTBPXHCXVWYOI-UHFFFAOYSA-O 0.000 claims description 7
- 229960002685 biotin Drugs 0.000 claims description 7
- 235000020958 biotin Nutrition 0.000 claims description 7
- 239000011616 biotin Substances 0.000 claims description 7
- 239000011575 calcium Substances 0.000 claims description 7
- 229910052791 calcium Inorganic materials 0.000 claims description 7
- 239000001110 calcium chloride Substances 0.000 claims description 7
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 7
- 229960003178 choline chloride Drugs 0.000 claims description 7
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 claims description 7
- QSWDMMVNRMROPK-UHFFFAOYSA-K chromium(3+) trichloride Chemical compound [Cl-].[Cl-].[Cl-].[Cr+3] QSWDMMVNRMROPK-UHFFFAOYSA-K 0.000 claims description 7
- GVPFVAHMJGGAJG-UHFFFAOYSA-L cobalt dichloride Chemical compound [Cl-].[Cl-].[Co+2] GVPFVAHMJGGAJG-UHFFFAOYSA-L 0.000 claims description 7
- JZCCFEFSEZPSOG-UHFFFAOYSA-L copper(II) sulfate pentahydrate Chemical compound O.O.O.O.O.[Cu+2].[O-]S([O-])(=O)=O JZCCFEFSEZPSOG-UHFFFAOYSA-L 0.000 claims description 7
- 238000012136 culture method Methods 0.000 claims description 7
- 238000012258 culturing Methods 0.000 claims description 7
- 235000000639 cyanocobalamin Nutrition 0.000 claims description 7
- 239000011666 cyanocobalamin Substances 0.000 claims description 7
- 229960001305 cysteine hydrochloride Drugs 0.000 claims description 7
- SVABQOITNJTVNJ-UHFFFAOYSA-N diphenyl-2-pyridylphosphine Chemical compound C1=CC=CC=C1P(C=1N=CC=CC=1)C1=CC=CC=C1 SVABQOITNJTVNJ-UHFFFAOYSA-N 0.000 claims description 7
- MSJMDZAOKORVFC-SEPHDYHBSA-L disodium fumarate Chemical compound [Na+].[Na+].[O-]C(=O)\C=C\C([O-])=O MSJMDZAOKORVFC-SEPHDYHBSA-L 0.000 claims description 7
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 7
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 claims description 7
- 239000000194 fatty acid Substances 0.000 claims description 7
- 229960000304 folic acid Drugs 0.000 claims description 7
- 235000019152 folic acid Nutrition 0.000 claims description 7
- 239000011724 folic acid Substances 0.000 claims description 7
- 229960002989 glutamic acid Drugs 0.000 claims description 7
- 229960002885 histidine Drugs 0.000 claims description 7
- 229960000367 inositol Drugs 0.000 claims description 7
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 7
- SURQXAFEQWPFPV-UHFFFAOYSA-L iron(2+) sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Fe+2].[O-]S([O-])(=O)=O SURQXAFEQWPFPV-UHFFFAOYSA-L 0.000 claims description 7
- 229960000310 isoleucine Drugs 0.000 claims description 7
- 229960003136 leucine Drugs 0.000 claims description 7
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 7
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 7
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 7
- CNFDGXZLMLFIJV-UHFFFAOYSA-L manganese(II) chloride tetrahydrate Chemical compound O.O.O.O.[Cl-].[Cl-].[Mn+2] CNFDGXZLMLFIJV-UHFFFAOYSA-L 0.000 claims description 7
- ISPYRSDWRDQNSW-UHFFFAOYSA-L manganese(II) sulfate monohydrate Chemical compound O.[Mn+2].[O-]S([O-])(=O)=O ISPYRSDWRDQNSW-UHFFFAOYSA-L 0.000 claims description 7
- 229960004452 methionine Drugs 0.000 claims description 7
- RRIWRJBSCGCBID-UHFFFAOYSA-L nickel sulfate hexahydrate Chemical compound O.O.O.O.O.O.[Ni+2].[O-]S([O-])(=O)=O RRIWRJBSCGCBID-UHFFFAOYSA-L 0.000 claims description 7
- 229940116202 nickel sulfate hexahydrate Drugs 0.000 claims description 7
- 235000010333 potassium nitrate Nutrition 0.000 claims description 7
- 239000004323 potassium nitrate Substances 0.000 claims description 7
- 229960002429 proline Drugs 0.000 claims description 7
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims description 7
- 229960004172 pyridoxine hydrochloride Drugs 0.000 claims description 7
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 claims description 7
- 239000011764 pyridoxine hydrochloride Substances 0.000 claims description 7
- 229960002477 riboflavin Drugs 0.000 claims description 7
- 235000019192 riboflavin Nutrition 0.000 claims description 7
- 239000002151 riboflavin Substances 0.000 claims description 7
- 238000005070 sampling Methods 0.000 claims description 7
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 7
- 229960001153 serine Drugs 0.000 claims description 7
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 claims description 7
- 239000011780 sodium chloride Substances 0.000 claims description 7
- BBMHARZCALWXSL-UHFFFAOYSA-M sodium dihydrogenphosphate monohydrate Chemical compound O.[Na+].OP(O)([O-])=O BBMHARZCALWXSL-UHFFFAOYSA-M 0.000 claims description 7
- 239000011775 sodium fluoride Substances 0.000 claims description 7
- 235000013024 sodium fluoride Nutrition 0.000 claims description 7
- 235000019294 sodium fumarate Nutrition 0.000 claims description 7
- CMZUMMUJMWNLFH-UHFFFAOYSA-N sodium metavanadate Chemical compound [Na+].[O-][V](=O)=O CMZUMMUJMWNLFH-UHFFFAOYSA-N 0.000 claims description 7
- 239000011781 sodium selenite Substances 0.000 claims description 7
- 235000015921 sodium selenite Nutrition 0.000 claims description 7
- 229960001471 sodium selenite Drugs 0.000 claims description 7
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 claims description 7
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 7
- 229960000344 thiamine hydrochloride Drugs 0.000 claims description 7
- 235000019190 thiamine hydrochloride Nutrition 0.000 claims description 7
- 239000011747 thiamine hydrochloride Substances 0.000 claims description 7
- 229960002898 threonine Drugs 0.000 claims description 7
- 229960004295 valine Drugs 0.000 claims description 7
- RZLVQBNCHSJZPX-UHFFFAOYSA-L zinc sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Zn+2].[O-]S([O-])(=O)=O RZLVQBNCHSJZPX-UHFFFAOYSA-L 0.000 claims description 7
- DUNKXUFBGCUVQW-UHFFFAOYSA-J zirconium tetrachloride Chemical compound Cl[Zr](Cl)(Cl)Cl DUNKXUFBGCUVQW-UHFFFAOYSA-J 0.000 claims description 7
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 6
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 claims description 6
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 claims description 6
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 6
- 229960005305 adenosine Drugs 0.000 claims description 6
- 229960005261 aspartic acid Drugs 0.000 claims description 6
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 claims description 6
- PHIQPXBZDGYJOG-UHFFFAOYSA-N sodium silicate nonahydrate Chemical compound O.O.O.O.O.O.O.O.O.[Na+].[Na+].[O-][Si]([O-])=O PHIQPXBZDGYJOG-UHFFFAOYSA-N 0.000 claims description 6
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 claims description 6
- 229940045145 uridine Drugs 0.000 claims description 6
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 claims description 5
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 claims description 5
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 claims description 5
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 claims description 5
- 239000001744 Sodium fumarate Substances 0.000 claims description 5
- 229960002104 cyanocobalamin Drugs 0.000 claims description 5
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 claims description 5
- 229940061607 dibasic sodium phosphate Drugs 0.000 claims description 5
- 230000003203 everyday effect Effects 0.000 claims description 5
- 229940029575 guanosine Drugs 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 claims description 5
- 229940005573 sodium fumarate Drugs 0.000 claims description 5
- 230000002354 daily effect Effects 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- IFQSXNOEEPCSLW-DKWTVANSSA-N L-cysteine hydrochloride Chemical compound Cl.SC[C@H](N)C(O)=O IFQSXNOEEPCSLW-DKWTVANSSA-N 0.000 claims description 3
- 238000011001 backwashing Methods 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 claims description 2
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 claims description 2
- 229940028334 follicle stimulating hormone Drugs 0.000 claims description 2
- SDVVLIIVFBKBMG-UHFFFAOYSA-N penta-2,4-dienoic acid Chemical compound OC(=O)C=CC=C SDVVLIIVFBKBMG-UHFFFAOYSA-N 0.000 claims description 2
- 238000011218 seed culture Methods 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims 1
- 239000000835 fiber Substances 0.000 abstract description 4
- 230000003321 amplification Effects 0.000 abstract description 3
- 239000012634 fragment Substances 0.000 abstract description 3
- 238000003199 nucleic acid amplification method Methods 0.000 abstract description 3
- 238000002360 preparation method Methods 0.000 abstract 1
- 239000013587 production medium Substances 0.000 abstract 1
- 239000000306 component Substances 0.000 description 24
- 239000000047 product Substances 0.000 description 16
- 238000001514 detection method Methods 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 238000004113 cell culture Methods 0.000 description 7
- 238000004114 suspension culture Methods 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 238000004140 cleaning Methods 0.000 description 6
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000011550 stock solution Substances 0.000 description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- FGDZQCVHDSGLHJ-UHFFFAOYSA-M rubidium chloride Chemical compound [Cl-].[Rb+] FGDZQCVHDSGLHJ-UHFFFAOYSA-M 0.000 description 4
- 239000004017 serum-free culture medium Substances 0.000 description 4
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 4
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 4
- YODUIMCJDQUOPA-QRPNPIFTSA-M sodium;(2s)-2-amino-3-(4-hydroxyphenyl)propanoate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CC1=CC=C(O)C=C1 YODUIMCJDQUOPA-QRPNPIFTSA-M 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 3
- VLSOAXRVHARBEQ-UHFFFAOYSA-N [4-fluoro-2-(hydroxymethyl)phenyl]methanol Chemical compound OCC1=CC=C(F)C=C1CO VLSOAXRVHARBEQ-UHFFFAOYSA-N 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 238000007664 blowing Methods 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 229960001031 glucose Drugs 0.000 description 3
- 235000001727 glucose Nutrition 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229960001614 levamisole Drugs 0.000 description 3
- 230000002572 peristaltic effect Effects 0.000 description 3
- 238000005086 pumping Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000010257 thawing Methods 0.000 description 3
- 239000011573 trace mineral Substances 0.000 description 3
- 235000013619 trace mineral Nutrition 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003839 Human Proteins Human genes 0.000 description 2
- 108090000144 Human Proteins Proteins 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 2
- 229910001626 barium chloride Inorganic materials 0.000 description 2
- 238000010923 batch production Methods 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229940102127 rubidium chloride Drugs 0.000 description 2
- 229910001961 silver nitrate Inorganic materials 0.000 description 2
- 235000009518 sodium iodide Nutrition 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 1
- RIPZAYPXOPSKEE-DKWTVANSSA-N (2r)-2-amino-3-sulfanylpropanoic acid;hydrate Chemical compound O.SC[C@H](N)C(O)=O RIPZAYPXOPSKEE-DKWTVANSSA-N 0.000 description 1
- WQZBIMQFROXVSY-MCDZGGTQSA-N (2r,3r,4s,5r)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol;sodium Chemical compound [Na].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O WQZBIMQFROXVSY-MCDZGGTQSA-N 0.000 description 1
- FMGRPEQSMWQKHM-QTNFYWBSSA-N (2s)-2-aminopentanedioic acid;sodium;hydrate Chemical compound O.[Na].OC(=O)[C@@H](N)CCC(O)=O FMGRPEQSMWQKHM-QTNFYWBSSA-N 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- DGRCWXMFZIFJNI-MINUCSRNSA-L O.[Na+].[Na+].N[C@@H](CCC(O)=O)C([O-])=O.N[C@@H](CCC(O)=O)C([O-])=O Chemical compound O.[Na+].[Na+].N[C@@H](CCC(O)=O)C([O-])=O.N[C@@H](CCC(O)=O)C([O-])=O DGRCWXMFZIFJNI-MINUCSRNSA-L 0.000 description 1
- 238000012356 Product development Methods 0.000 description 1
- 238000006935 Simonis synthesis reaction Methods 0.000 description 1
- 239000004115 Sodium Silicate Substances 0.000 description 1
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- GKHOLUJNLGYFHA-UHFFFAOYSA-N [Na].CC(C)=O Chemical compound [Na].CC(C)=O GKHOLUJNLGYFHA-UHFFFAOYSA-N 0.000 description 1
- 238000004115 adherent culture Methods 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229910052911 sodium silicate Inorganic materials 0.000 description 1
- NTHWMYGWWRZVTN-UHFFFAOYSA-N sodium silicate Chemical compound [Na+].[Na+].[O-][Si]([O-])=O NTHWMYGWWRZVTN-UHFFFAOYSA-N 0.000 description 1
- 239000001119 stannous chloride Substances 0.000 description 1
- 235000011150 stannous chloride Nutrition 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
- C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
- C12N2500/16—Magnesium; Mg chelators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/22—Zinc; Zn chelators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/24—Iron; Fe chelators; Transferrin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/34—Sugars
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/36—Lipids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/40—Nucleotides, nucleosides or bases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/46—Amines, e.g. putrescine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Reproductive Health (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明公开了一种高密度培养重组CHO细胞生产人促卵泡激素的方法、培养基及其应用,属于生物制药领域,制备方法包括:将CHO细胞复苏后,使用基础培养基进行细胞密度扩增;当活细胞密度达到一定密度后,使用生产培养基进行灌注培养:新鲜生产培养基补加到生物反应器罐体内,反应器罐体外连接的中空纤维截留装置使CHO细胞被截留,使细胞能够维持很高的密度和活力;当反应器内细胞处于稳定状态时,开启CHO细胞表达产物收集。本发明通过生物反应器搅拌培养和外接细胞截留装置可以截留细胞,过滤碎片和表达的蛋白,为细胞生长提供高密度环境,同时中空纤维柱的反向冲洗,降低了纤维堵塞,延长了细胞的高密度培养时间,显著提升批次产量。
Description
技术领域
本发明涉及生物制药领域,特别是涉及一种高密度灌注培养重组CHO细胞生产人促卵泡激素的方法、培养基及其应用。
背景技术
人促卵泡激素(human follicle stimulating hormone,hFSH)是垂体前叶嗜碱性细胞合成和分泌的一种糖蛋白类促性腺激素,属于异二聚体糖蛋白家族,由独立的基因分别编码的两条非共价连接的α链和β链组成。最初医学使用的促卵泡激素是从绝经期妇女的尿液中提纯的,存在人源蛋白污染的风险,而且批次间产品差异较大,很难满足市场的需求(Prevost R R.Recombinant Follicle-Stimulating Hormone:New Biotechnology forInfertility[J].Human Reproduction Update,1998,18(5):1001-1010.)。随着分子生物学的快速发展,市场上出现了重组人促卵泡激素产品,纯度更高,没有人源蛋白污染,批间一致性和安全性更高,副反应更低(Santi D,Simoni M.Biosimilar recombinantfollicle stimulating hormones in infertility treatment[J].Expert Opinion onBiological Therapy,2014,14(10):1399-1409.)。
大多数FSH产品都是通过重组中国仓鼠卵巢细胞(Chinese Hamster Ovary cell,CHO)生产的。在培养上,最初采用含有血清的培养基进行转瓶或微载体纸片贴壁培养(Recombinant follicle stimulating hormone:development of the firstbiotechnology product for the treatment of infertility.Recombinant Human FSHProduct Development Group.hum Reproduction Update.1998,4(6):862-881),添加血清有潜在的动物病毒感染的风险,且不利于纯化。随着无血清培养基的出现,国内有了关于大规模悬浮培养工艺研究的报道(CHO细胞表达rhFSH的大规模无血清培养工艺的研究,吉林大学,2012),但该工艺在种子复苏阶段仍需要添加血清,后期虽然去除了血清,但表达量不高。
中国专利CN 105462909 A中提到了一种高效表达人促卵泡激素的CHO细胞的培养方法,从种子复苏到细胞培养,全程采用商业化无血清培养基和补料培养,细胞最高密度可达4×107个/ml,表达量达到40mg/L,5L反应器批次生产可达到140mg,但细胞培养时间较短,批次产量仍然不高。
因此,提供一种能够提高批次产量、安全高效表达人促卵泡激素的培养方法显得尤为重要。
发明内容
本发明要解决的技术问题是提供一种提高批次产量、安全高效的高活细胞密度(Variable cell density,VCD)培养重组CHO细胞生产人促卵泡激素的方法及其应用。
为解决上述技术问题,本发明提供的技术方案如下:
一方面,本发明提供一种高密度灌注培养重组CHO细胞生产人促卵泡激素的方法,包括如下步骤:
1)将CHO细胞复苏活化后,使用基础培养基进行培养获得种子悬液;
2)当种子培养液达到一定密度后,采用灌注培养基进行灌注培养;
灌注培养的方法:将新鲜生产培养基补加到生物反应器罐体内,反应器的外部连接中空纤维截留装置,通过对CHO细胞进行截留和反冲洗维持CHO细胞较高的密度和活力;使用所述的灌注培养基进行灌注和反冲洗;
3)当反应器内细胞密度及活性处于稳定状态时,开启CHO细胞表达产物收集,表达产物为人促卵泡激素;
其中,所述的灌注培养基为无血清、无蛋白以及化学成份明确的细胞培养基,所述的灌注培养基由基础培养基和补料培养基按照一定比例混合而成,相应的,所述基础培养基也为无血清、无蛋白以及化学成份明确的细胞培养基。反应器罐体外连接的中空纤维截留装置使CHO细胞被截留在生物反应器罐体内部,相同重量的培养基上清可以透过中空纤维装置被从罐体内排出。灌注过程使细胞代谢废物被实时从罐体内去除,而新鲜营养物质被实时补加到罐体内,从而使CHO细胞能够维持很高的密度,活力及生产时间。
进一步地,具体步骤为:
1)将重组CHO细胞复苏活化后,利用无血清、无蛋白、化学成份明确的基础细胞培养基重悬培养,获得种子细胞溶液;其中,所述无血清、无蛋白化学成份明确的基础细胞培养基中含有5000~8000mg/mL葡萄糖;
2)将种子细胞溶液接种到5L种子反应器中进行培养,生物反应器中初始细胞密度为0.5~1.0×106个/mL,每日取样进行细胞计数,使用基础细胞培养基扩增培养至一定体积和密度;
3)接种50L生物反应器,进行灌注培养:每天灌注一定比例的灌注培养基,当反应器内细胞处于稳定状态时,开启CHO细胞表达产物收集;
4)维持细胞最高密度在60~90×106个/mL,优选为60~85×106个/mL,当细胞活率低于90%时,停止收液。本领域细胞培养的技术人员,可以采用适当的方式从反应器内取出一部分细胞,使反应器内的细胞密度维持在目标范围内。
即本发明通过种子细胞复苏后,经摇瓶培养达到一定密度后,接种生物反应器悬浮培养,扩增到一定体积和密度后,开始进行灌注培养,并不定期除去一部分细胞,当细胞生长达到稳态后,降低细胞的培养温度,开始进行灌注培养,收集细胞表达产物。定期检测细胞的培养参数,如细胞密度、细胞活率、葡糖糖水平、乳酸水平、氨累积量、pH值、温度、溶解氧等,监测细胞培养状态。
本发明提供了一种重组人促卵泡激素的培养方法,通过采用无血清、无蛋白、化学成份明确培养基以及悬浮培养外加细胞截留装置进行灌注培养的方式,生物反应器搅拌培养和外接细胞截留装置可以截留细胞,过滤碎片和表达的蛋白,为细胞生长提供高密度环境,同时中空纤维柱的反向冲洗,降低了纤维堵塞,延长了细胞的高密度培养时间,显著提升批次产量,而且收获的细胞液不含细胞,简化了纯化前处理步骤,能明显降低成本和提升产品质量。解决了现有技术中无血清培养基表达低、表达时间短、批次产品产量低等问题。
灌注培养是指细胞接种反应器后,每日取样计数,待细胞达到一定密度后,放出一部分培养基,使用中空纤维柱截留细胞,使用柱子的反向冲洗功能将细胞送回反应器,通过灌注培养既可以不断的给细胞提供营养,又能带走代谢产物,维持细胞良好的生长环境,延长细胞的表达时间,从而提高细胞的产量。保证细胞密度和长期置换培养基,维持细胞的高密度和高活力。
一般地,细胞种子液获得为:从液氮罐取出一支重组人促卵泡激素CHO细胞,采用常规方法复苏后,使用无血清、无蛋白、化学成份明确的基础细胞培养基培养,达到一定密度后,即为种子液。
进一步地,所述步骤2)中,种子液细胞接种5L种子反应器后,每日取样计数,补充基础培养基至一定体积后,接种50L生物反应器,开始进行灌注培养和表达产物收集。
进一步地,所述步骤2)中反应器的培养条件为:温度为36~37℃,pH值6.8~7.1,溶氧30%~60%,线速度为0.6~1.2m/s。优选的,所述步骤2)中反应器中的培养体积为4.0~4.5L。优选的,所述步骤2)中在反应器中的细胞培养时间为5~7天。
进一步地,所述步骤3)中灌注培养的条件为:温度为34℃,pH值6.8~7.1,溶氧30%~60%,线速度为1.0m/s。反应器中的培养体积为40~45L。优选的,所述步骤3)的灌注细胞培养时间为30~60天。
进一步地,培养基的灌注量随着细胞密度的逐渐增加而增加,细胞特异性灌注速率(Cell Specific Perfusion Rate,CSPR)为40~60pL·(c·d)-1。
进一步地,灌注培养过程中,保持葡萄糖浓度大于1000mg/mL。
进一步地,所述纤维柱内的中空纤维膜由亲水性聚砜/聚氯乙烯制成。
另一方面,提供一种上述灌注培养中使用的高密度灌注培养重组CHO细胞生产人促卵泡激素的灌注培养基,所述灌注培养基为无血清、无蛋白、化学成份明确的灌注培养基,所述灌注培养基由70%~90%的基础培养基和10%~30%的补料培养基构成,含有葡萄糖、氨基酸、维生素、盐、微量元素及其它成份。
基础培养基具体成份如下:300~500mg/ml的L-盐酸精氨酸,100~300mg/ml的L-精氨酸,100~200mg/ml的L-天冬酰胺,1200~1800mg/ml的L-一水天冬酰胺,200~400mg/ml的L-天冬氨酸,200~400mg/ml的L-一水天冬氨酸钠盐,200~300mg/ml的L-半胱氨酸,200~400mg/ml的L-一水半胱氨酸盐酸盐,200~400mg/ml的L-2盐酸半胱氨酸,200~400mg/ml的L-谷氨酸,100~300mg/ml的L-一水谷氨酸钠,200~300mg/ml的L-谷氨酰胺,100~200mg/ml的甘氨酸,100~200mg/ml的L-组氨酸,200~400mg/ml的L-一水组氨酸盐酸,200~400mg/ml的L-异亮氨酸,300~500mg/ml的L-亮氨酸,400~600mg/ml的L-盐酸赖氨酸,100~300mg/ml的L-赖氨酸,100~300mg/ml的L-甲硫氨酸,200~400mg/ml的L-苯丙氨酸,200~400mg/ml的L-脯氨酸,300~500mg/ml的L-丝氨酸,200~400mg/ml的L-苏氨酸,100~300mg/ml的L-色氨酸,200~400mg/ml的L-2水酪氨酸钠,200~400mg/ml的L-缬氨酸,0.1~0.3mg/ml的生物素,50~70mg/ml的氯化胆碱,2~4mg/ml的氰钴胺,10~15mg/ml的叶酸,100~150mg/ml的肌醇,12~18mg/ml的烟酰胺,18~25mg/ml的D-戊二烯酸钙,18~25mg/ml的盐酸吡哆醇,1~3mg/ml的核黄素,12~15mg/ml的盐酸硫胺素,0.4~1mg/ml的DL-α-硫辛酸,0.006~0.008mg/ml的偏钒酸铵,0.005~0.008mg/ml的四水钼酸铵,0.05~0.1mg/ml的五水硫酸铜,0.001~0.003mg/ml的四水合氯化锰,0.004~0.006mg/ml的一水硫酸锰,0.001~0.003mg/ml的六水硫酸镍,0.004~0.006mg/ml的溴化钾,0.004~0.006mg/ml的偏钒酸钠,0.5~1.5mg/ml的九水偏硅酸钠,0.001~0.002mg/ml的二水氯化亚锡,0.2~0.5mg/ml的七水硫酸亚铁,20~40mg/ml的氯化镁,40~60mg/ml的硫酸镁,300~400mg/ml的氯化钾,0.03~0.05mg/ml的硝酸钾,50~80mg/ml的一水磷酸二氢钠,20~40mg/ml的碳酸氢钠,50~80mg/ml的腐胺,100~140mg/ml的丙酮酸钠,5000~8000mg/ml的葡萄糖,400~600mg/ml的磷酸氢二钠,0.03~0.1mg/ml的亚硒酸钠,2~10mg/ml的七水硫酸锌,1~5mg/ml的乙醇胺,100~150mg/ml的氯化钙,1~10mg/ml的柠檬酸铁,1000~5000mg/ml的氯化钠,200~400mg/ml的富马酸二钠。
补料培养基具体成份如下:20~30mg/L的L-丙氨酸,2000~2500mg/L的L-精氨酸,4000~5000mg/L的L-天门冬氨酸,1200~1500mg/L的L-半胱氨酸,7000~8000mg/L的L-谷氨酸,30~40mg/L的甘氨酸,1200~1500mg/L的L-一水盐酸组氨酸,200~300mg/L的L-脯氨酸,5000~6000mg/L的L-亮氨酸,4000~5000mg/L的L-盐酸赖氨酸,800~1000mg/L的L-蛋氨酸,2000~3000mg/L的L-苯丙氨酸,1000~2000mg/L的L-脯氨酸,3000~4000mg/L的L-丝氨酸,2000~3000mg/L的L-苏氨酸,1500~2000mg/L的L-色氨酸,2000~3000mg/L的L-酪氨酸钠,3000~4000mg/L的L-缬氨酸,10~20mg/L的维生素C,4~8mg/L的维生素H,2000~3000mg/L的氯化胆碱,20~30mg/L的叶酸,200~300mg/L的肌醇,20~30mg/L的烟酰胺,5~10mg/L的盐酸吡哆醇,20~30mg/L的盐酸硫胺素,2~5mg/L的维生素B12,20~30mg/L的泛酸钙,30~50mg/L的磷酸氢二钠,400~500mg/L的磷酸二氢钠,0.02~0.05mg/L的硫酸铜,20~30mg/L的硫酸锌,0.00005~0.0001mg/L的氯化锰,0.1~0.2mg/L的硅酸钠,0.0005~0.001mg/L的偏钒酸铵,0.0001~0.0002mg/L的硫酸镍,0.001~0.003mg/L的氯化铝,0.001~0.003mg/L的硝酸银,0.0001~0.0002mg/L的氯化钡,0.0001~0.0003mg/L的氯化钾,0.003~0.005mg/L的溴化钠,0.0001~0.0003mg/L的碘化钠,0.001~0.002mg/L的氯化铷,0.003~0.005mg/L的氯化锆,0.0001~0.0003mg/L的氯化铬,0.002~0.005mg/L的氯化钴,0.003~0.005mg/L的氟化钠,20~30mg/L的柠檬酸铁,800~1200mg/L的F-68,10000~30000mg/L的葡萄糖,2~5mg/L的DL-α-脂肪酸,200~300mg/L的丙酮酸钠,5~10mg/L的腺苷,5~10mg/L的尿苷,5~10mg/L的胞苷,5~10mg/L的鸟苷。
优选地,所述无血清、无蛋白、化学成份明确的灌注培养基由80%~90%的基础培养基和10%~20%的补料培养基构成,含有葡萄糖、氨基酸、维生素、盐、微量元素及其它成份。
基础培养基具体成份如下:350~450mg/ml的L-盐酸精氨酸,120~200mg/ml的L-精氨酸,100~180mg/ml的L-天冬酰胺,1300~1500mg/ml的L-一水天冬酰胺,250~350mg/ml的L-天冬氨酸,300~350mg/ml的L-一水天冬氨酸钠盐,200~250mg/ml的L-半胱氨酸,250~350mg/ml的L-一水半胱氨酸盐酸盐,250~350mg/ml的L-2盐酸半胱氨酸,350~400mg/ml的L-谷氨酸,200~250mg/ml的L-一水谷氨酸钠,200~250mg/ml的L-谷氨酰胺,100~150mg/ml的甘氨酸,150~200mg/ml的L-组氨酸,250~350mg/ml的L-一水组氨酸盐酸,300~400mg/ml的L-异亮氨酸,400~500mg/ml的L-亮氨酸,500~600mg/ml的L-盐酸赖氨酸,200~300mg/ml的L-赖氨酸,200~300mg/ml的L-甲硫氨酸,280~350mg/ml的L-苯丙氨酸,300~380mg/ml的L-脯氨酸,400~450mg/ml的L-丝氨酸,300~350mg/ml的L-苏氨酸,200~280mg/ml的L-色氨酸,250~320mg/ml的L-2水酪氨酸钠,300~350mg/ml的L-缬氨酸,0.1~0.2mg/ml的生物素,60~70mg/ml的氯化胆碱,3~4mg/ml的氰钴胺,10~12mg/ml的叶酸,100~120mg/ml的肌醇,13~17mg/ml的烟酰胺,19~22mg/ml的D-戊二烯酸钙,18~23mg/ml的盐酸吡哆醇,1.2~2mg/ml的核黄素,13~14mg/ml的盐酸硫胺素,0.6~0.8mg/ml的DL-α-硫辛酸,0.007~0.008mg/ml的偏钒酸铵,0.006~0.007mg/ml的四水钼酸铵,0.08~0.1mg/ml的五水硫酸铜,0.001~0.002mg/ml的四水合氯化锰,0.005~0.006mg/ml的一水硫酸锰,0.001~0.002mg/ml的六水硫酸镍,0.005~0.006mg/ml的溴化钾,0.005~0.006mg/ml的偏钒酸钠,0.8~1.2mg/ml的九水偏硅酸钠,0.001~0.0015mg/ml的二水氯化亚锡,0.4~0.5mg/ml的七水硫酸亚铁,28~32mg/ml的氯化镁,48~55mg/ml的硫酸镁,320~350mg/ml的氯化钾,0.035~0.045mg/ml的硝酸钾,60~65mg/ml的一水磷酸二氢钠,30~35mg/ml的碳酸氢钠,72~76mg/ml的腐胺,110~120mg/ml的丙酮酸钠,6000~7000mg/ml的葡萄糖,450~500mg/ml的磷酸氢二钠,0.035~0.05mg/ml的亚硒酸钠,5~8mg/ml的七水硫酸锌,3~4mg/ml的乙醇胺,100~120mg/ml的氯化钙,5~8mg/ml的柠檬酸铁,2000~3000mg/ml的氯化钠,300~350mg/ml的富马酸二钠。
补料培养基具体成份如下:24~28mg/L的L-丙氨酸,2200~2400mg/L的L-精氨酸,4500~4800mg/L的L-天门冬氨酸,1300~1400mg/L的L-半胱氨酸,7500~7800mg/L的L-谷氨酸,35~38mg/L的甘氨酸,1200~1300mg/L的L-一水盐酸组氨酸,260~290mg/L的L-脯氨酸,5600~5800mg/L的L-亮氨酸,4500~4800mg/L的L-盐酸赖氨酸,900~1000mg/L的L-蛋氨酸,2400~2800mg/L的L-苯丙氨酸,1500~1800mg/L的L-脯氨酸,3300~3800mg/L的L-丝氨酸,2600~2900mg/L的L-苏氨酸,1500~1800mg/L的L-色氨酸,2300~2600mg/L的L-酪氨酸钠,3500~3800mg/L的L-缬氨酸,12~15mg/L的维生素C,5~7mg/L的维生素H,2300~2500mg/L的氯化胆碱,24~28mg/L的叶酸,220~280mg/L的肌醇,25~29mg/L的烟酰胺,6~8mg/L的盐酸吡哆醇,24~26mg/L的盐酸硫胺素,3~5mg/L的维生素B12,25~27mg/L的泛酸钙,35~45mg/L的磷酸氢二钠,420~480mg/L的磷酸二氢钠,0.03~0.045mg/L的硫酸铜,25~27mg/L的硫酸锌,0.000055~0.000095mg/L的氯化锰,0.15~0.18mg/L的硅酸钠,0.0008~0.001mg/L的偏钒酸铵,0.00012~0.00016mg/L的硫酸镍,0.0012~0.0025mg/L的氯化铝,0.0015~0.0025mg/L的硝酸银,0.00012~0.00014mg/L的氯化钡,0.00016~0.00025mg/L的氯化钾,0.004~0.0045mg/L的溴化钠,0.00012~0.00024mg/L的碘化钠,0.0012~0.0015mg/L的氯化铷,0.0035~0.0045mg/L的氯化锆,0.00015~0.0002mg/L的氯化铬,0.0025~0.0045mg/L的氯化钴,0.004~0.0045mg/L的氟化钠,26~28mg/L的柠檬酸铁,900~1000mg/L的F-68,15000~25000mg/L的葡萄糖,3~4mg/L的DL-α-脂肪酸,260~280mg/L的丙酮酸钠,6~9mg/L的腺苷,6~9mg/L的尿苷,6~9mg/L的胞苷,6~9mg/L的鸟苷。
进一步优选地,所述无血清、无蛋白、化学成份明确的灌注培养基由90%的基础培养基和10%的补料培养基构成,含有葡萄糖、氨基酸、维生素、盐、微量元素及其它成份。
细胞基础培养基包括:400.45mg/ml的L-盐酸精氨酸,150.66mg/ml的L-精氨酸,130.89mg/ml的L-天冬酰胺,1498.68mg/ml的L-一水天冬酰胺,345.65mg/ml的L-天冬氨酸,300.12mg/ml的L-一水天冬氨酸钠盐,246.54mg/ml的L-半胱氨酸,345.45mg/ml的L-一水半胱氨酸盐酸盐,300.00mg/ml的L-2盐酸半胱氨酸,371.78mg/ml的L-谷氨酸,213.54mg/ml的L-一水谷氨酸钠,245.56mg/ml的L-谷氨酰胺,125.34mg/ml的甘氨酸,192.62mg/ml的L-组氨酸,300.12mg/ml的L-一水组氨酸盐酸,380.00mg/ml的L-异亮氨酸,460.43mg/ml的L-亮氨酸,556.76mg/ml的L-盐酸赖氨酸,234.54mg/ml的L-赖氨酸,235.57mg/ml的L-甲硫氨酸,294.11mg/ml的L-苯丙氨酸,308.61mg/ml的L-脯氨酸,435.65mg/ml的L-丝氨酸,332.45mg/ml的L-苏氨酸,207.12mg/ml的L-色氨酸,278.34mg/ml的L-2水酪氨酸钠,300.32mg/ml的L-缬氨酸,0.12mg/ml的生物素,65.67mg/ml的氯化胆碱,3.65mg/ml的氰钴胺,11.23mg/ml的叶酸,116.43mg/ml的肌醇,15.55mg/ml的烟酰胺,20.12mg/ml的D-戊二烯酸钙,19.65mg/ml的盐酸吡哆醇,1.55mg/ml的核黄素,13.43mg/ml的盐酸硫胺素,0.72mg/ml的DL-α-硫辛酸,0.00786mg/ml的偏钒酸铵,0.00653mg/ml的四水钼酸铵,0.0906mg/ml的五水硫酸铜,0.00186mg/ml的四水合氯化锰,0.00554mg/ml的一水硫酸锰,0.00120mg/ml的六水硫酸镍,0.00540mg/ml的溴化钾,0.00529mg/ml的偏钒酸钠,1.03mg/ml的九水偏硅酸钠,0.00101mg/ml的二水氯化亚锡,0.43mg/ml的七水硫酸亚铁,30.03mg/ml的氯化镁,50.75mg/ml的硫酸镁,341.75mg/ml的氯化钾,0.04mg/ml的硝酸钾,64.93mg/ml的一水磷酸二氢钠,34.56mg/ml的碳酸氢钠,75.6mg/ml的腐胺,113.91mg/ml的丙酮酸钠,6543.68mg/ml的葡萄糖,489.75mg/ml的磷酸氢二钠,0.04mg/ml的亚硒酸钠,5.58mg/ml的七水硫酸锌,3.67mg/ml的乙醇胺,103.82mg/ml的氯化钙,6.87mg/ml的柠檬酸铁,2065.43mg/ml的氯化钠,320mg/ml的富马酸二钠组成。
补料培养基包括:25mg/L的L-丙氨酸,2300mg/L的L-精氨酸,4600mg/L的L-天门冬氨酸,1350mg/L的L-半胱氨酸,7600mg/L的L-谷氨酸,36mg/L的甘氨酸,1250mg/L的L-一水盐酸组氨酸,280mg/L的L-脯氨酸,5650mg/L的L-亮氨酸,4600mg/L的L-盐酸赖氨酸,950mg/L的L-蛋氨酸,2500mg/L的L-苯丙氨酸,1600mg/L的L-脯氨酸,3500mg/L的L-丝氨酸,2800mg/L的L-苏氨酸,1600mg/L的L-色氨酸,2500mg/L的L-酪氨酸钠,3700mg/L的L-缬氨酸,14.5mg/L的维生素C,6.5mg/L的维生素H,2380mg/L的氯化胆碱,25mg/L的叶酸,260mg/L的肌醇,28mg/L的烟酰胺,6.5mg/L的盐酸吡哆醇,25.5mg/L的盐酸硫胺素,4.5mg/L的维生素B12,26.5mg/L的泛酸钙,40mg/L的磷酸氢二钠,450mg/L的磷酸二氢钠,0.038mg/L的硫酸铜,25.5mg/L的硫酸锌,0.000075mg/L的氯化锰,0.165mg/L的硅酸钠,0.0009mg/L的偏钒酸铵,0.00015mg/L的硫酸镍,0.0024mg/L的氯化铝,0.002mg/L的硝酸银,0.00013mg/L的氯化钡,00018mg/L的氯化钾,0.0042mg/L的溴化钠,0.00018mg/L的碘化钠,0.0014mg/L的氯化铷,0.004mg/L的氯化锆,0.00018mg/L的氯化铬,0.0035mg/L的氯化钴,0.0042mg/L的氟化钠,27.5mg/L的柠檬酸铁,950mg/L的F-68,18000mg/L的葡萄糖,3.5mg/L的DL-α-脂肪酸,275mg/L的丙酮酸钠,8.5mg/L的腺苷,8.5mg/L的尿苷,8.5mg/L的胞苷,8.5mg/L的鸟苷。
另一方面,提供一种人促卵泡激素的应用,所述的人促卵泡激素是通过所述的高密度灌注培养重组CHO细胞生产人促卵泡激素的方法制备得到。
采用这样的设计后,本发明至少具有以下优点:
(1)本发明提供了一种重组人促卵泡激素的培养方法,通过采用无血清、无蛋白、化学成份明确的培养基以及悬浮培养外加细胞截留装置进行灌注培养的方式,生物反应器搅拌培养和外接细胞截留装置(即中空纤维截留装置)可以截留细胞,过滤碎片和表达的蛋白,为细胞生长提供高密度环境,同时中空纤维柱的反向冲洗,降低了纤维堵塞,延长了细胞的高密度培养时间,显著提升批次产量,而且收获的细胞液不含细胞,简化了纯化前处理步骤,能明显降低成本和提升产品质量。解决了现有技术中无血清培养基表达低、表达时间短、批次产品产量低等问题。
(2)本发明通过种子细胞复苏后,经摇瓶培养达到一定密度后,接种生物反应器悬浮培养,当培养液中的葡萄糖消耗到一定水平后,开始进行灌注培养,并不定期除去一部分细胞,当细胞生长达到稳态后,降低细胞的培养温度,开始进行灌注培养,定期检测细胞的培养参数,如细胞密度、细胞活率、葡糖糖水平、乳酸水平、氨累积量、pH值、温度、溶解氧等,监测细胞培养状态。
附图说明
上述仅是本发明技术方案的概述,为了能够更清楚了解本发明的技术手段,以下结合附图与具体实施方式对本发明作进一步的详细说明。
图1是本发明的实施例1的重组人促卵泡激素细胞密度和活率随时间变化曲线图;
图2是本发明的实施例2的重组人促卵泡激素细胞密度和活率随时间变化曲线图;
图3是本发明的实施例3的重组人促卵泡激素细胞密度和活率随时间变化曲线图。
具体实施方式
下面结合实施例对本发明作进一步说明,但本发明不局限于下述实施例,任何在本发明的启示下得出的与本发明相同或相近似的产品,均在保护范围之内。
以下实施例所用的仪器、耗材、试剂均为本领域常规仪器、耗材和试剂,本领域的专业技术人员均可以通过商业渠道获得。
实施例1
(1)细胞复苏获得种子细胞液
从液氮罐中取出一支细胞,37℃水浴融化后,将细胞转移至15ml无菌离心管内,加入5ml 37℃预热的无血清、无蛋白、化学成份明确的基础细胞培养基,轻轻吹打,混匀,800rpm,离心5min,弃掉上清,重新加入5ml新鲜培养基重悬,将细胞悬液转移至125ml透气摇瓶内,补充15ml培养基,于37℃,120rpm,8%CO2,70%~90%湿度下培养。每隔一天取样计数,补充培养基,维持细胞密度4~6×106个/ml。摇瓶的体积从125ml,250ml,500ml,1000ml,2000ml逐步放大,经过7~10天的扩增,种子体积达到500ml左右,密度3.6×106个/ml。
本实施例无血清、无蛋白、化学成份明确的基础培养基组成为:380.86mg/ml的L-盐酸精氨酸,124.68mg/ml的L-精氨酸,110.09mg/ml的L-天冬酰胺,1413.54mg/ml的L-一水天冬酰胺,350.78mg/ml的L-天冬氨酸,322.55mg/ml的L-一水天冬氨酸钠盐,256.51mg/ml的L-半胱氨酸,300.08mg/ml的L-一水半胱氨酸盐酸盐,350.06mg/ml的L-2盐酸半胱氨酸,354.78mg/ml的L-谷氨酸,200.00mg/ml的L-一水谷氨酸钠,232.12mg/ml的L-谷氨酰胺,124.35mg/ml的甘氨酸,200.12mg/ml的L-组氨酸,323.43mg/ml的L-一水组氨酸盐酸,371.78mg/ml的L-异亮氨酸,438.45mg/ml的L-亮氨酸,550.60mg/ml的L-盐酸赖氨酸,221.26mg/ml的L-赖氨酸,230.00mg/ml的L-甲硫氨酸,311.54mg/ml的L-苯丙氨酸,300.89mg/ml的L-脯氨酸,422.65mg/ml的L-丝氨酸,327.98mg/ml的L-苏氨酸,200.00mg/ml的L-色氨酸,261.44mg/ml的L-2水酪氨酸钠,300.56mg/ml的L-缬氨酸,0.14mg/ml的生物素,61.13mg/ml的氯化胆碱,3.56mg/ml的氰钴胺,10.34mg/ml的叶酸,110.56mg/ml的肌醇,14.58mg/ml的烟酰胺,19.57mg/ml的D-戊二烯酸钙,20.55mg/ml的盐酸吡哆醇,1.45mg/ml的核黄素,13.85mg/ml的盐酸硫胺素,0.69mg/ml的DL-α-硫辛酸,0.00754mg/ml的偏钒酸铵,0.00601mg/ml的四水钼酸铵,0.0832mg/ml的五水硫酸铜,0.00178mg/ml的四水合氯化锰,0.00544mg/ml的一水硫酸锰,0.00108mg/ml的六水硫酸镍,0.005mg/ml的溴化钾,0.00518mg/ml的偏钒酸钠,0.886mg/ml的九水偏硅酸钠,0.001mg/ml的二水氯化亚锡,0.40mg/ml的七水硫酸亚铁,28.50mg/ml的氯化镁,49.90mg/ml的硫酸镁,320.76mg/ml的氯化钾,0.038mg/ml的硝酸钾,63.65mg/ml的一水磷酸二氢钠,34.55mg/ml的碳酸氢钠,75.5mg/ml的腐胺,112.65mg/ml的丙酮酸钠,6478.98mg/ml的葡萄糖,476.57mg/ml的磷酸氢二钠,0.035mg/ml的亚硒酸钠,6.73mg/ml的七水硫酸锌,3.45mg/ml的乙醇胺,100.56mg/ml的氯化钙,5.78mg/ml的柠檬酸铁,2000.23mg/ml的氯化钠,311.54mg/ml的富马酸二钠。
本实施例无血清、无蛋白、化学成份明确的补料培养基组成为:25mg/L的L-丙氨酸,2300mg/L的L-精氨酸,4600mg/L的L-天门冬氨酸,1350mg/L的L-半胱氨酸,7600mg/L的L-谷氨酸,36mg/L的甘氨酸,1250mg/L的L-一水盐酸组氨酸,280mg/L的L-脯氨酸,5650mg/L的L-亮氨酸,4600mg/L的L-盐酸赖氨酸,950mg/L的L-蛋氨酸,2500mg/L的L-苯丙氨酸,1600mg/L的L-脯氨酸,3500mg/L的L-丝氨酸,2800mg/L的L-苏氨酸,1600mg/L的L-色氨酸,2500mg/L的L-酪氨酸钠,3700mg/L的L-缬氨酸,14.5mg/L的维生素C,6.5mg/L的维生素H,2380mg/L的氯化胆碱,25mg/L的叶酸,260mg/L的肌醇,28mg/L的烟酰胺,6.5mg/L的盐酸吡哆醇,25.5mg/L的盐酸硫胺素,4.5mg/L的维生素B12,26.5mg/L的泛酸钙,40mg/L的磷酸氢二钠,450mg/L的磷酸二氢钠,0.038mg/L的硫酸铜,25.5mg/L的硫酸锌,0.000075mg/L的氯化锰,0.165mg/L的硅酸钠,0.0009mg/L的偏钒酸铵,0.00015mg/L的硫酸镍,0.0024mg/L的氯化铝,0.002mg/L的硝酸银,0.00013mg/L的氯化钡,00018mg/L的氯化钾,0.0042mg/L的溴化钠,0.00018mg/L的碘化钠,0.0014mg/L的氯化铷,0.004mg/L的氯化锆,0.00018mg/L的氯化铬,0.0035mg/L的氯化钴,0.0042mg/L的氟化钠,27.5mg/L的柠檬酸铁,950mg/L的F-68,18000mg/L的葡萄糖,3.5mg/L的DL-α-脂肪酸,275mg/L的丙酮酸钠,8.5mg/L的腺苷,8.5mg/L的尿苷,8.5mg/L的胞苷,8.5mg/L的鸟苷。
本实施例中无血清、无蛋白、化学成份明确的灌注培养基组成为:80%的基础培养基和20%的补料培养基。
(2)接种5L种子反应器
种子反应器接种后体积4L,细胞密度4.5×105个/ml,培养温度37℃,线速度1.0m/s,溶氧30%~60%,pH值6.8~7.1。每日取样计数。
(3)灌注培养
当细胞密度达到5×106个/ml时,接种50L生物反应器,接种体积40L,开始进行灌注培养,开启中空纤维截留装置的换液管路和澄清液收集管路,关闭清洗管路与反向冲洗管路,澄清液收集结束,开启反向冲洗,冲洗结束后,关闭管路,运行清洁管路进行主体持续清洁。当细胞处于稳定状态后,降低培养温度至34℃,线速度1.0m/s,溶氧30%~60%,pH值6.8~7.1,持续灌注,并收液,维持葡萄糖含量大于1g/L,直至细胞活率低于90%,停止收液。从接种反应器算起整个灌注培养一共维持了35天,共收液体2100L,为培养体积的52.5倍,表达量为15mg/L,批次产量为31500mg。
本实施例中培养基灌注量的调整策略为:CSPR为40~60pL·(c·d)-1,维持细胞密度在60~85×106个/mL左右,多余的细胞使用蠕动泵抽除去。本实施例的细胞密度和细胞活率变化曲线见图1所示,使其一直维持在较高的细胞密度和细胞活率水平上。
对收获的原液进行质量检测,检测方法参见《中华人民共和国药典》(2015年版),检测标准参考果纳芬进口注射液质量标准,检测结果见表1。
表1重组人促卵泡激素原液的检测结果
实施例2
(1)细胞复苏获得种子细胞液
从液氮罐取出一支细胞,37℃水浴融化后,将细胞转移至15ml无菌离心管内,加入5ml 37℃预热的无血清、无蛋白、化学成份明确的基础细胞培养基,轻轻吹打,混匀,800rpm,离心5min,弃掉上清,重新加入5ml新鲜培养基重悬,将细胞悬液转移至125ml透气摇瓶内,补充15ml培养基,于37℃,120rpm,8%CO2,70%~90%湿度下培养。每隔一天取样计数,补充培养基,维持细胞密度3~4×106个/ml。摇瓶的体积从125ml,250ml,500ml,1000ml,2000ml逐步放大,经过7~10天的扩增,种子体积达到600ml左右,密度3.8.×106个/ml。
本实施例中的无血清、无蛋白、化学成份明确的基础培养基为:400.45mg/ml的L-盐酸精氨酸,150.66mg/ml的L-精氨酸,130.89mg/ml的L-天冬酰胺,1498.68mg/ml的L-一水天冬酰胺,345.65mg/ml的L-天冬氨酸,300.12mg/ml的L-一水天冬氨酸钠盐,246.54mg/ml的L-半胱氨酸,345.45mg/ml的L-一水半胱氨酸盐酸盐,300.00mg/ml的L-2盐酸半胱氨酸,371.78mg/ml的L-谷氨酸,213.54mg/ml的L-一水谷氨酸钠,245.56mg/ml的L-谷氨酰胺,125.34mg/ml的甘氨酸,192.62mg/ml的L-组氨酸,300.12mg/ml的L-一水组氨酸盐酸,380.00mg/ml的L-异亮氨酸,460.43mg/ml的L-亮氨酸,556.76mg/ml的L-盐酸赖氨酸,234.54mg/ml的L-赖氨酸,235.57mg/ml的L-甲硫氨酸,294.11mg/ml的L-苯丙氨酸,308.61mg/ml的L-脯氨酸,435.65mg/ml的L-丝氨酸,332.45mg/ml的L-苏氨酸,207.12mg/ml的L-色氨酸,278.34mg/ml的L-2水酪氨酸钠,300.32mg/ml的L-缬氨酸,0.12mg/ml的生物素,65.67mg/ml的氯化胆碱,3.65mg/ml的氰钴胺,11.23mg/ml的叶酸,116.43mg/ml的肌醇,15.55mg/ml的烟酰胺,20.12mg/ml的D-戊二烯酸钙,19.65mg/ml的盐酸吡哆醇,1.55mg/ml的核黄素,13.43mg/ml的盐酸硫胺素,0.72mg/ml的DL-α-硫辛酸,0.00786mg/ml的偏钒酸铵,0.00653mg/ml的四水钼酸铵,0.0906mg/ml的五水硫酸铜,0.00186mg/ml的四水合氯化锰,0.00554mg/ml的一水硫酸锰,0.00120mg/ml的六水硫酸镍,0.00540mg/ml的溴化钾,0.00529mg/ml的偏钒酸钠,1.03mg/ml的九水偏硅酸钠,0.00101mg/ml的二水氯化亚锡,0.43mg/ml的七水硫酸亚铁,30.03mg/ml的氯化镁,50.75mg/ml的硫酸镁,341.75mg/ml的氯化钾,0.04mg/ml的硝酸钾,64.93mg/ml的一水磷酸二氢钠,34.56mg/ml的碳酸氢钠,75.6mg/ml的腐胺,113.91mg/ml的丙酮酸钠,6543.68mg/ml的葡萄糖,489.75mg/ml的磷酸氢二钠,0.04mg/ml的亚硒酸钠,5.58mg/ml的七水硫酸锌,3.67mg/ml的乙醇胺,103.82mg/ml的氯化钙,6.87mg/ml的柠檬酸铁,2065.43mg/ml的氯化钠,320mg/ml的富马酸二钠。
本实施例无血清、无蛋白、化学成份明确的补料培养基组成为:25mg/L的L-丙氨酸,2300mg/L的L-精氨酸,4600mg/L的L-天门冬氨酸,1350mg/L的L-半胱氨酸,7600mg/L的L-谷氨酸,36mg/L的甘氨酸,1250mg/L的L-一水盐酸组氨酸,280mg/L的L-脯氨酸,5650mg/L的L-亮氨酸,4600mg/L的L-盐酸赖氨酸,950mg/L的L-蛋氨酸,2500mg/L的L-苯丙氨酸,1600mg/L的L-脯氨酸,3500mg/L的L-丝氨酸,2800mg/L的L-苏氨酸,1600mg/L的L-色氨酸,2500mg/L的L-酪氨酸钠,3700mg/L的L-缬氨酸,14.5mg/L的维生素C,6.5mg/L的维生素H,2380mg/L的氯化胆碱,25mg/L的叶酸,260mg/L的肌醇,28mg/L的烟酰胺,6.5mg/L的盐酸吡哆醇,25.5mg/L的盐酸硫胺素,4.5mg/L的维生素B12,26.5mg/L的泛酸钙,40mg/L的磷酸氢二钠,450mg/L的磷酸二氢钠,0.038mg/L的硫酸铜,25.5mg/L的硫酸锌,0.000075mg/L的氯化锰,0.165mg/L的硅酸钠,0.0009mg/L的偏钒酸铵,0.00015mg/L的硫酸镍,0.0024mg/L的氯化铝,0.002mg/L的硝酸银,0.00013mg/L的氯化钡,00018mg/L的氯化钾,0.0042mg/L的溴化钠,0.00018mg/L的碘化钠,0.0014mg/L的氯化铷,0.004mg/L的氯化锆,0.00018mg/L的氯化铬,0.0035mg/L的氯化钴,0.0042mg/L的氟化钠,27.5mg/L的柠檬酸铁,950mg/L的F-68,18000mg/L的葡萄糖,3.5mg/L的DL-α-脂肪酸,275mg/L的丙酮酸钠,8.5mg/L的腺苷,8.5mg/L的尿苷,8.5mg/L的胞苷,8.5mg/L的鸟苷。
本实施例无血清、无蛋白、化学成份明确的灌注培养基组成为:85%的基础培养基和15%的补料培养基。
(2)接种5L种子反应器
5L种子反应器接种后体积4.3L,细胞密度5.3×105个/ml,培养温度37℃,线速度1.0m/s,溶氧30%~60%,pH值6.8~7.1。每日取样计数。
(3)灌注培养
当细胞密度达到5×106个/ml时,接种50L生物反应器,接种体积40L,开始进行灌注培养,开启中空纤维截留装置的换液管路和澄清液收集管路,关闭清洗管路与反向冲洗管路,澄清液收集结束,开启反向冲洗,冲洗结束后,关闭管路,运行清洁管路进行主体持续清洁。当细胞处于稳定状态后,降低培养温度至34℃,线速度1.0m/s,溶氧30%~60%,pH值6.8~7.1,持续灌注,维持葡萄糖含量大于1g/L,直至细胞活率低于90%,停止收液。从接种反应器算起整个灌注培养一共维持了42天,共收液体2520L,为培养体积的63倍,表达量为22mg/L,批次产量为55440mg。
本实施例中培养基灌注量的调整策略为:
CSPR为40~60pL·(c·d)-1,维持细胞密度在60~80×106个/mL左右,多余的细胞使用蠕动泵抽除去。
本实施例的细胞密度和细胞活率变化曲线见图2所示,使其一直维持在较高的细胞密度和细胞活率水平上。
对收获的原液进行质量检测,检测方法参见《中华人民共和国药典》(2015年版),检测标准参考果纳芬进口注射液质量标准,检测结果见表2。
表2重组人促卵泡激素原液的检测结果
实施例3
(1)细胞复苏获得种子细胞液
从液氮罐取出一支细胞,37℃水浴融化后,将细胞转移至15ml无菌离心管内,加入5ml 37℃预热的无血清、无蛋白、化学成份明确的基础细胞培养基,轻轻吹打,混匀,800rpm,离心5min,弃掉上清,重新加入5ml新鲜培养基重悬,将细胞悬液转移至125ml透气摇瓶内,补充15ml培养基,于37℃,120rpm,8%CO2,70%~90%湿度下培养。每隔一天取样计数,补充培养基,维持细胞密度3~4×106个/ml。摇瓶的体积从125ml,250ml,500ml,1000ml,2000ml逐步放大,经过7~10天的扩增,种子体积达到600ml左右,密度3.5×106个/ml。
本实施例无血清、无蛋白、化学成份明确的基础细胞培养基组成为:430.54mg/ml的L-盐酸精氨酸,172.78mg/ml的L-精氨酸,166.70mg/ml的L-天冬酰胺,1499.76mg/ml的L-一水天冬酰胺,347.88mg/ml的L-天冬氨酸,335.54mg/ml的L-一水天冬氨酸钠盐,248.80mg/ml的L-半胱氨酸,347.85mg/ml的L-一水半胱氨酸盐酸盐,321.65mg/ml的L-2盐酸半胱氨酸,389.91mg/ml的L-谷氨酸,245.60mg/ml的L-一水谷氨酸钠,244.67mg/ml的L-谷氨酰胺,138.86mg/ml的甘氨酸,195.67mg/ml的L-组氨酸,322.08mg/ml的L-一水组氨酸盐酸,394.62mg/ml的L-异亮氨酸,489.65mg/ml的L-亮氨酸,556.76mg/ml的L-盐酸赖氨酸,235.54mg/ml的L-赖氨酸,243.87mg/ml的L-甲硫氨酸,311.76mg/ml的L-苯丙氨酸,316.76mg/ml的L-脯氨酸,443.55mg/ml的L-丝氨酸,340.00mg/ml的L-苏氨酸,210.07mg/ml的L-色氨酸,280.87mg/ml的L-2水酪氨酸钠,300.32mg/ml的L-缬氨酸,0.15mg/ml的生物素,65.67mg/ml的氯化胆碱,3.80mg/ml的氰钴胺,11.54mg/ml的叶酸,115.52mg/ml的肌醇,15.06mg/ml的烟酰胺,20.00mg/ml的D-戊二烯酸钙,19.65mg/ml的盐酸吡哆醇,1.55mg/ml的核黄素,13.67mg/ml的盐酸硫胺素,0.65mg/ml的DL-α-硫辛酸,0.00785mg/ml的偏钒酸铵,0.00655mg/ml的四水钼酸铵,0.091mg/ml的五水硫酸铜,0.00185mg/ml的四水合氯化锰,0.0055mg/ml的一水硫酸锰,0.0015mg/ml的六水硫酸镍,0.0055mg/ml的溴化钾,0.00530mg/ml的偏钒酸钠,1.00mg/ml的九水偏硅酸钠,0.00101mg/ml的二水氯化亚锡,0.45mg/ml的七水硫酸亚铁,30.05mg/ml的氯化镁,50.45mg/ml的硫酸镁,345.83mg/ml的氯化钾,0.04mg/ml的硝酸钾,65.00mg/ml的一水磷酸二氢钠,34.12mg/ml的碳酸氢钠,75.5mg/ml的腐胺,115.0mg/ml的丙酮酸钠,6500.0mg/ml的葡萄糖,485.45mg/ml的磷酸氢二钠,0.04mg/ml的亚硒酸钠,5.60mg/ml的七水硫酸锌,3.55mg/ml的乙醇胺,105.40mg/ml的氯化钙,5.65mg/ml的柠檬酸铁,2124.5mg/ml的氯化钠,320.50mg/ml的富马酸二钠。
本实施例无血清、无蛋白、化学成份明确的补料培养基组成为:25mg/L的L-丙氨酸,2300mg/L的L-精氨酸,4600mg/L的L-天门冬氨酸,1350mg/L的L-半胱氨酸,7600mg/L的L-谷氨酸,36mg/L的甘氨酸,1250mg/L的L-一水盐酸组氨酸,280mg/L的L-脯氨酸,5650mg/L的L-亮氨酸,4600mg/L的L-盐酸赖氨酸,950mg/L的L-蛋氨酸,2500mg/L的L-苯丙氨酸,1600mg/L的L-脯氨酸,3500mg/L的L-丝氨酸,2800mg/L的L-苏氨酸,1600mg/L的L-色氨酸,2500mg/L的L-酪氨酸钠,3700mg/L的L-缬氨酸,14.5mg/L的维生素C,6.5mg/L的维生素H,2380mg/L的氯化胆碱,25mg/L的叶酸,260mg/L的肌醇,28mg/L的烟酰胺,6.5mg/L的盐酸吡哆醇,25.5mg/L的盐酸硫胺素,4.5mg/L的维生素B12,26.5mg/L的泛酸钙,40mg/L的磷酸氢二钠,450mg/L的磷酸二氢钠,0.038mg/L的硫酸铜,25.5mg/L的硫酸锌,0.000075mg/L的氯化锰,0.165mg/L的硅酸钠,0.0009mg/L的偏钒酸铵,0.00015mg/L的硫酸镍,0.0024mg/L的氯化铝,0.002mg/L的硝酸银,0.00013mg/L的氯化钡,00018mg/L的氯化钾,0.0042mg/L的溴化钠,0.00018mg/L的碘化钠,0.0014mg/L的氯化铷,0.004mg/L的氯化锆,0.00018mg/L的氯化铬,0.0035mg/L的氯化钴,0.0042mg/L的氟化钠,27.5mg/L的柠檬酸铁,950mg/L的F-68,18000mg/L的葡萄糖,3.5mg/L的DL-α-脂肪酸,275mg/L的丙酮酸钠,8.5mg/L的腺苷,8.5mg/L的尿苷,8.5mg/L的胞苷,8.5mg/L的鸟苷。
本实施例无血清、无蛋白、化学成份明确的灌注培养基组成为:90%的基础培养基和10%的补料培养基。
(2)接种5L种子反应器
种子反应器接种后体积42L,细胞密度5.0×105个/ml,培养温度37℃,线速度1.0m/s,溶氧30%~60%,pH值6.8~7.1。每日取样计数。
(3)灌注培养
当细胞密度达到5×106个/ml时,接种50L生物反应器,接种体积40L,开始进行灌注培养,开启中空纤维截留装置的换液管路和澄清液收集管路,关闭清洗管路与反向冲洗管路,澄清液收集结束,开启反向冲洗,冲洗结束后,关闭管路,运行清洁管路进行主体持续清洁。当细胞处于稳定状态后,降低培养温度至34℃,线速度1.0m,溶氧30%~60%,pH值6.8~7.1,持续灌注,维持葡萄糖含量大于1g/L,直至细胞活率低于90%,停止收液。从接种反应器算起整个灌注培养一共维持了52天,共收液体3500L,为培养体积的87.5倍,表达量为25mg/L,批次产量为87500mg。
本实施例中培养基灌注量的调整策略为:
CSPR为40~60pL·(c·d)-1,维持细胞密度在60~80×106个/mL左右,多余的细胞使用蠕动泵抽除去。
本实施例的细胞密度和细胞活率变化曲线见图2所示,使其一直维持在较高的细胞密度和细胞活率水平上。
对收获的原液进行质量检测,检测方法参见《中华人民共和国药典》(2015年版),检测标准参考果纳芬进口注射液质量标准,检测结果见表3。
表3重组人促卵泡激素原液的检测结果
本发明的发明人,通过不断研究发现,本发明无血清无蛋白细胞培养基与灌注培养工艺配合使用,批次表达量不仅受到细胞培养基配方的影响,如实施例1中,使用80%基础培养基+20%补料培养基作为灌注培养基,重组人促卵泡激素的批次产量为31.5g,而实施例2的批次产量是55.44g,实施例3的批次产量是87.5g,说明在相同的灌注培养工艺下,培养基对产物产量影响很大,而且不同培养基组份对产品的质量也有较大的影响,从三个实施例的原液检测结果可见,不同的培养基组份下,重组人促卵泡激素的氧化亚基,解离亚基,等电点,唾液酸含量以及产品的生物活性都有较大的影响。我们在前期的小试研究中也发现,灌注培养中降温培养也对灌注培养时间和批次表达量都有较大的影响,发明人经过不断研究确定了最终的培养基配方和培养条件。
综上,本发明的细胞培养方法结合培养基和灌注培养工艺的调整,使灌注培养的一个周期可达30~60天,甚至更久,使重组CHO细胞表达人促卵泡激素长时间处于较高水平,批次产量在30g以上,甚至达到87.5g以上,与传统的悬浮培养相比,批次生产量提高了几十倍,有利于工业化生产应用,而且采用无血清、无蛋白细胞培养基,使获得的人促卵泡激素减少感染风险,且该培养基成本低廉,适于推广使用。
以上所述,仅是本发明的较佳实施例而已,并非对本发明作任何形式上的限制,本领域技术人员利用上述揭示的技术内容做出些许简单修改、等同变化或修饰,均落在本发明的保护范围内。
Claims (4)
1.一种高密度灌注培养重组CHO细胞生产人促卵泡激素的方法,其特征在于,包括如下步骤:
1)将CHO细胞复苏活化后,使用基础培养基进行培养获得种子悬液;
2)当种子培养液达到一定密度后,采用灌注培养基进行灌注培养;
灌注培养的方法:将新鲜生产培养基补加到生物反应器罐体内,反应器的外部连接中空纤维截留装置,通过对CHO细胞进行截留和反冲洗维持CHO细胞较高的密度和活力;使用所述的灌注培养基进行灌注和反冲洗;
3)当反应器内细胞密度及活力处于稳定状态时,开启CHO细胞表达产物收集,表达产物为人促卵泡激素;
其中,所述的灌注培养基为无血清、无蛋白以及化学成份明确的细胞培养基,所述的灌注培养基由基础培养基和补料培养基按照一定比例混合而成,相应的,所述基础培养基也为无血清、无蛋白以及化学成份明确的细胞培养基;
所述的无血清、无蛋白以及化学成份明确的灌注培养基是由90%的基础培养基与10%的补料培养基组成,具体成份如下:
1)所述基础培养基具体成份如下:400.45mg/ml的L-盐酸精氨酸,150.66mg/ml的L-精氨酸,130.89mg/ml的L-天冬酰胺,1498.68mg/ml的L-一水天冬酰胺,345.65mg/ml的L-天冬氨酸,300.12mg/ml的L-一水天冬氨酸钠盐,246.54mg/ml的L-半胱氨酸,345.45mg/ml的L-一水半胱氨酸盐酸盐,300.00mg/ml的L-2盐酸半胱氨酸,371.78mg/ml的L-谷氨酸,213.54mg/ml的L-一水谷氨酸钠,245.56mg/ml的L-谷氨酰胺,125.34mg/ml的甘氨酸,192.62mg/ml的L-组氨酸,300.12mg/ml的L-一水组氨酸盐酸,380.00mg/ml的L-异亮氨酸,460.43mg/ml的L-亮氨酸,556.76mg/ml的L-盐酸赖氨酸,234.54mg/ml的L-赖氨酸,235.57mg/ml的L-甲硫氨酸,294.11mg/ml的L-苯丙氨酸,308.61mg/ml的L-脯氨酸,435.65mg/ml的L-丝氨酸,332.45mg/ml的L-苏氨酸,207.12mg/ml的L-色氨酸,278.34mg/ml的L-2水酪氨酸钠,300.32mg/ml的L-缬氨酸,0.12mg/ml的生物素,65.67mg/ml的氯化胆碱,3.65mg/ml的氰钴胺,11.23mg/ml的叶酸,116.43mg/ml的肌醇,15.55mg/ml的烟酰胺,20.12mg/ml的D-戊二烯酸钙,19.65mg/ml的盐酸吡哆醇,1.55mg/ml的核黄素,13.43mg/ml的盐酸硫胺素,0.72mg/ml的DL-α-硫辛酸,0.00786mg/ml的偏钒酸铵,0.00653mg/ml的四水钼酸铵,0.0906mg/ml的五水硫酸铜,0.00186mg/ml的四水合氯化锰,0.00554mg/ml的一水硫酸锰,0.00120mg/ml的六水硫酸镍,0.00540mg/ml的溴化钾,0.00529mg/ml的偏钒酸钠,1.03mg/ml的九水偏硅酸钠,0.00101mg/ml的二水氯化亚锡,0.43mg/ml的七水硫酸亚铁,30.03mg/ml的氯化镁,50.75mg/ml的硫酸镁,341.75mg/ml的氯化钾,0.04mg/ml的硝酸钾,64.93mg/ml的一水磷酸二氢钠,34.56mg/ml的碳酸氢钠,75.6mg/ml的腐胺,113.91mg/ml的丙酮酸钠,6543.68mg/ml的葡萄糖,489.75mg/ml的磷酸氢二钠,0.04mg/ml的亚硒酸钠,5.58mg/ml的七水硫酸锌,3.67mg/ml的乙醇胺,103.82mg/ml的氯化钙,6.87mg/ml的柠檬酸铁,2065.43mg/ml的氯化钠,320mg/ml的富马酸二钠组成;
2)所述补料培养基具体成份如下:25mg/L的L-丙氨酸,2300mg/L的L-精氨酸,4600mg/L的L-天门冬氨酸,1350mg/L的L-半胱氨酸,7600mg/L的L-谷氨酸,36mg/L的甘氨酸,1250mg/L的L-一水盐酸组氨酸,280mg/L的L-脯氨酸,5650mg/L的L-亮氨酸,4600mg/L的L-盐酸赖氨酸,950mg/L的L-蛋氨酸,2500mg/L的L-苯丙氨酸,1600mg/L的L-脯氨酸,3500mg/L的L-丝氨酸,2800mg/L的L-苏氨酸,1600mg/L的L-色氨酸,2500mg/L的L-酪氨酸钠,3700mg/L的L-缬氨酸,14.5mg/L的维生素C,6.5mg/L的维生素H,2380mg/L的氯化胆碱,25mg/L的叶酸,260mg/L的肌醇,28mg/L的烟酰胺,6.5mg/L的盐酸吡哆醇,25.5mg/L的盐酸硫胺素,4.5mg/L的维生素B12,26.5mg/L的泛酸钙,40mg/L的磷酸氢二钠,450mg/L的磷酸二氢钠,0.038mg/L的硫酸铜,25.5mg/L的硫酸锌,0.000075mg/L的氯化锰,0.165mg/L的硅酸钠,0.0009mg/L的偏钒酸铵,0.00015mg/L的硫酸镍,0.0024mg/L的氯化铝,0.002mg/L的硝酸银,0.00013mg/L的氯化钡,00018mg/L的氯化钾,0.0042mg/L的溴化钠,0.00018mg/L的碘化钠,0.0014mg/L的氯化铷,0.004mg/L的氯化锆,0.00018mg/L的氯化铬,0.0035mg/L的氯化钴,0.0042mg/L的氟化钠,27.5mg/L的柠檬酸铁,950mg/L的F-68,18000mg/L的葡萄糖,3.5mg/L的DL-α-脂肪酸,275mg/L的丙酮酸钠,8.5mg/L的腺苷,8.5mg/L的尿苷,8.5mg/L的胞苷,8.5mg/L的鸟苷。
2.根据权利要求1所述的高密度灌注培养重组CHO细胞生产人促卵泡激素的方法,其特征在于,包括如下步骤;
1)所述的培养方法为,将重组CHO细胞复苏活化后,利用基础培养基重悬培养,获得种子细胞溶液;其中,所述基础培养基中含有5000~8000mg/mL葡萄糖;
2)将种子细胞溶液接种到5L种子反应器中进行培养,生物反应器中细胞密度为0.5~1.0×106个/mL,每日取样进行细胞计数;
3)种子液达到一定密度后,接种50L生物反应器,进行灌注培养:每日灌注一定比例的灌注培养基,当反应器内细胞处于稳定状态时,开启CHO细胞表达产物收集;
4)维持细胞最高密度在60~85×106个/mL,当细胞活率低于90%时,停止收液。
3.根据权利要求1至2任一所述的高密度灌注培养重组CHO细胞生产人促卵泡激素的方法,其特征在于,所述步骤3)中反应器的培养条件为:温度为33~37℃,pH值6.8~7.1,溶氧30%~60%,线速度0.6~1.2m/s;
和/或,所述步骤4)中灌注培养的条件为:温度为34℃,pH6.8~7.1,溶氧30%~60%,搅拌线速度1.0m/s;
和/或,所述步骤4)中:接种第二天后开始灌注培养工艺,细胞特异性灌注速率为40~60pL·(c·d)-1。
4.根据权利要求1至2任一所述的高密度灌注培养重组CHO细胞生产人促卵泡激素的方法,其特征在于,灌注培养过程中,保持葡萄糖浓度大于1000mg/mL。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910398124.2A CN110042137B (zh) | 2019-05-14 | 2019-05-14 | 高密度灌注培养重组cho细胞生产人促卵泡激素的方法、培养基及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910398124.2A CN110042137B (zh) | 2019-05-14 | 2019-05-14 | 高密度灌注培养重组cho细胞生产人促卵泡激素的方法、培养基及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110042137A CN110042137A (zh) | 2019-07-23 |
CN110042137B true CN110042137B (zh) | 2023-02-28 |
Family
ID=67281976
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910398124.2A Active CN110042137B (zh) | 2019-05-14 | 2019-05-14 | 高密度灌注培养重组cho细胞生产人促卵泡激素的方法、培养基及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110042137B (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112680396B (zh) * | 2019-10-18 | 2024-04-05 | 东曜药业有限公司 | 单抗或重组蛋白大规模生产中细胞扩增的方法 |
CN113088480B (zh) * | 2019-12-23 | 2022-10-11 | 信达生物制药(苏州)有限公司 | 一种用于cho细胞的培养基及其用途 |
CN111996161B (zh) * | 2020-09-08 | 2022-03-04 | 依科赛生物科技(太仓)有限公司 | 一种cho细胞无血清无蛋白培养基及其用途 |
CN113151183A (zh) * | 2021-04-21 | 2021-07-23 | 赵峻岭 | 一种促进蛋白表达的培养基添加物及其应用 |
CN113337562B (zh) * | 2021-05-24 | 2022-06-03 | 宁波人健药业集团股份有限公司 | 使用CHO细胞高效发酵生产rhCG的方法 |
CN114606200A (zh) * | 2022-02-10 | 2022-06-10 | 上海迈邦生物科技有限公司 | Sp2/0细胞培养基及生产重组犬细小病毒单克隆抗体的方法 |
CN116790483B (zh) * | 2023-08-22 | 2023-10-20 | 苏州依科赛生物科技股份有限公司 | 一种cho细胞无血清培养基及其应用 |
CN118956767A (zh) * | 2024-09-20 | 2024-11-15 | 上海多宁生物科技股份有限公司 | 一种改善cho细胞生长代谢表达的培养方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105002242A (zh) * | 2015-07-23 | 2015-10-28 | 苏州康聚生物科技有限公司 | 用于cho细胞中高效表达重组人促甲状腺激素的无血清培养基及其应用 |
CN105462909A (zh) * | 2015-12-31 | 2016-04-06 | 哈药集团技术中心 | 一种高效表达人促卵泡激素的cho细胞的培养方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA200702434B (en) * | 2004-11-02 | 2008-08-27 | Ares Trading Sa | Serum-free cell culture medium for mammalian cells |
TWI369401B (en) * | 2005-07-05 | 2012-08-01 | Ares Trading Sa | Serum-free culture medium for the production of recombinant gonadotropins |
US10119117B2 (en) * | 2016-01-28 | 2018-11-06 | Nanogen Pharmaceutical Biotechnology Co., Ltd | Universal, glycosylation enhancer, completely chemically defined medium formulation |
-
2019
- 2019-05-14 CN CN201910398124.2A patent/CN110042137B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105002242A (zh) * | 2015-07-23 | 2015-10-28 | 苏州康聚生物科技有限公司 | 用于cho细胞中高效表达重组人促甲状腺激素的无血清培养基及其应用 |
CN105462909A (zh) * | 2015-12-31 | 2016-04-06 | 哈药集团技术中心 | 一种高效表达人促卵泡激素的cho细胞的培养方法 |
Non-Patent Citations (3)
Title |
---|
表达乙型肝炎表面抗原的重组CHO细胞无血清培养基的优化及生物反应器培养;滕小锘等;《中国生物制品学杂志》;20101031;第23卷(第10期);1080-1086 * |
重组人促卵泡激素在CHO细胞中的表达;何太平等;《中国生物制品学杂志》;20111220(第12期);1409-1412 * |
重组人促卵泡激素研究进展;刘金钏等;《中国药科大学学报》;20130625(第03期);283-288 * |
Also Published As
Publication number | Publication date |
---|---|
CN110042137A (zh) | 2019-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110042137B (zh) | 高密度灌注培养重组cho细胞生产人促卵泡激素的方法、培养基及其应用 | |
CN105018416B (zh) | 一种悬浮培养bhk-21细胞的无血清无动物源培养基及其配制方法 | |
CN111996161B (zh) | 一种cho细胞无血清无蛋白培养基及其用途 | |
CN105331659B (zh) | 改进的细胞培养基 | |
CN112795531B (zh) | 一种cho细胞无血清无蛋白培养基及其用途 | |
CN104593316B (zh) | 昆虫细胞无血清培养基及其应用 | |
CN101195817A (zh) | 一种杂交瘤细胞扩增培养基及其用途 | |
CN106635953B (zh) | 无血清无蛋白细胞培养基 | |
CN111019883B (zh) | Cho细胞悬浮培养的无血清无蛋白培养基及其用途 | |
CN1442478A (zh) | 体外生长哺乳动物细胞的改良方法 | |
CN101988047A (zh) | 一种低成本的昆虫细胞无血清培养基 | |
GB2153830A (en) | Protein production method | |
CN114606200A (zh) | Sp2/0细胞培养基及生产重组犬细小病毒单克隆抗体的方法 | |
CN113684175A (zh) | 一种贴壁细胞驯化悬浮细胞的方法 | |
CN107841482A (zh) | Mdck细胞无血清悬浮培养技术生产h9亚型流感疫苗 | |
CN102021139A (zh) | 一种中国仓鼠卵巢细胞培养基及其制备方法和应用 | |
CN111733126B (zh) | 一种Vero细胞无血清培养基及其用途 | |
CN116790477A (zh) | 一种支持cho细胞高密度培养的无血清培养基及其制备方法与应用 | |
CN104450815A (zh) | 一种提高异亮氨酸产量的发酵方法 | |
CN113528429A (zh) | 一种适用于hek293细胞的无血清培养基 | |
CN1772884A (zh) | 一种支持hek293细胞贴附培养的无动物来源成分无血清培养基 | |
CN106190909B (zh) | 副鸡嗜血杆菌b型株发酵培养基、其制备方法及其应用 | |
CN113122605B (zh) | 一种生产抗cd47抗体的培养基及发酵方法 | |
CN113846051B (zh) | 一种通用型化学成分限定cho细胞传代培养基及其应用 | |
CN116731956A (zh) | 一种哺乳动物细胞的培养基及其培养方法和抗体的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |